Loading...

Luz Saúde

ENXTLS:LUZ
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LUZ
ENXTLS
€535M
Market Cap
  1. Home
  2. PT
  3. Healthcare
Company description

Luz Saúde, S.A. operates a network of healthcare facilities. The last earnings update was 74 days ago. More info.


Add to Portfolio Compare Print
LUZ Share Price and Events
7 Day Returns
0%
ENXTLS:LUZ
1.9%
Europe Healthcare
1.6%
PT Market
1 Year Returns
-
ENXTLS:LUZ
-11.1%
Europe Healthcare
-7.6%
PT Market
LUZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Luz Saúde (LUZ) 0% 0% 0% - 53.4% -
Europe Healthcare 1.9% -3.7% -17.1% -11.1% 0.2% 59.3%
PT Market 1.6% -1.8% -11.2% -7.6% -45.2% -72.3%
1 Year Return vs Industry and Market
  • No trading data on LUZ.
  • No trading data on LUZ.
Price Volatility
LUZ
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Luz Saúde's competitors could be found in our database.

LUZ Value

 Is Luz Saúde undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Luz Saúde to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Luz Saúde.

ENXTLS:LUZ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year PT Government Bond Rate 1.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTLS:LUZ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PT Govt Bond Rate 1.5%
Equity Risk Premium S&P Global 8.5%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.43
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.431 (1 + (1- 21%) (57.6%))
0.627
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.51% + (0.8 * 8.49%)
8.3%

Discounted Cash Flow Calculation for ENXTLS:LUZ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Luz Saúde is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTLS:LUZ DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 36.60 39.02 41.61 44.36 47.29
Source Est @ 6.62% Est @ 6.62% Est @ 6.62% Est @ 6.62% Est @ 6.62%
Present Value
Discounted (@ 8.3%)
33.79 33.27 32.75 32.24 31.74
Present value of next 5 years cash flows €163.80
ENXTLS:LUZ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €47.29 × (1 + 1.51%) ÷ (8.3% – 1.51%)
€706.84
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €706.84 ÷ (1 + 8.3%)5
€474.40
ENXTLS:LUZ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €163.80 + €474.40
€638.20
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €638.20 / 95.54
€6.68
ENXTLS:LUZ Discount to Share Price
Calculation Result
Value per share (EUR) From above. €6.68
Current discount Discount to share price of €5.60
= -1 x (€5.60 - €6.68) / €6.68
16.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Luz Saúde is available for.
Intrinsic value
16%
Share price is €5.6 vs Future cash flow value of €6.68
Current Discount Checks
For Luz Saúde to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Luz Saúde's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Luz Saúde's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Luz Saúde's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Luz Saúde's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTLS:LUZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €0.19
ENXTLS:LUZ Share Price ** ENXTLS (2018-11-22) in EUR €5.6
Europe Healthcare Industry PE Ratio Median Figure of 60 Publicly-Listed Healthcare Companies 18.39x
Portugal Market PE Ratio Median Figure of 30 Publicly-Listed Companies 11.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Luz Saúde.

ENXTLS:LUZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTLS:LUZ Share Price ÷ EPS (both in EUR)

= 5.6 ÷ 0.19

30.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Luz Saúde is overvalued based on earnings compared to the Europe Healthcare industry average.
  • Luz Saúde is overvalued based on earnings compared to the Portugal market.
Price based on expected Growth
Does Luz Saúde's expected growth come at a high price?
Raw Data
ENXTLS:LUZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 30.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
15.4%per year
Europe Healthcare Industry PEG Ratio Median Figure of 36 Publicly-Listed Healthcare Companies 1.29x
Portugal Market PEG Ratio Median Figure of 18 Publicly-Listed Companies 1.77x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Luz Saúde, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Luz Saúde's assets?
Raw Data
ENXTLS:LUZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €2.54
ENXTLS:LUZ Share Price * ENXTLS (2018-11-22) in EUR €5.6
Europe Healthcare Industry PB Ratio Median Figure of 76 Publicly-Listed Healthcare Companies 1.93x
Portugal Market PB Ratio Median Figure of 41 Publicly-Listed Companies 1.06x
ENXTLS:LUZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTLS:LUZ Share Price ÷ Book Value per Share (both in EUR)

= 5.6 ÷ 2.54

2.2x

* Primary Listing of Luz Saúde.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Luz Saúde is overvalued based on assets compared to the Europe Healthcare industry average.
X
Value checks
We assess Luz Saúde's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Luz Saúde has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LUZ Future Performance

 How is Luz Saúde expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Luz Saúde, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Luz Saúde expected to grow at an attractive rate?
  • Luz Saúde's earnings growth is expected to exceed the low risk savings rate of 1.5%.
Growth vs Market Checks
  • Luz Saúde's earnings growth is expected to exceed the Portugal market average.
  • Unable to compare Luz Saúde's revenue growth to the Portugal market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTLS:LUZ Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTLS:LUZ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 15.4%
Europe Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Europe Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 7.4%
Portugal Market Earnings Growth Rate Market Cap Weighted Average 9%
Portugal Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTLS:LUZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTLS:LUZ Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 514 68 18
2018-03-31 498 64 17
2017-12-31 482 61 17
2017-09-30 471 56 17
2017-06-30 460 51 16
2017-03-31 454 46 16
2016-12-31 450 35 17
2016-09-30 449 27 19
2016-06-30 441 24 21
2016-03-31 431 23 23
2015-12-31 423 47 22
2015-09-30 416 40 20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Luz Saúde's earnings are expected to grow by 15.4% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Luz Saúde is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTLS:LUZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Luz Saúde Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTLS:LUZ Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 0.19
2018-03-31 0.18
2017-12-31 0.18
2017-09-30 0.17
2017-06-30 0.17
2017-03-31 0.16
2016-12-31 0.18
2016-09-30 0.20
2016-06-30 0.22
2016-03-31 0.24
2015-12-31 0.23
2015-09-30 0.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Luz Saúde will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Luz Saúde's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Luz Saúde has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LUZ Past Performance

  How has Luz Saúde performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Luz Saúde's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Luz Saúde's year on year earnings growth rate has been positive over the past 5 years.
  • Luz Saúde's 1-year earnings growth exceeds its 5-year average (10.1% vs 1.5%)
  • Luz Saúde's earnings growth has not exceeded the Europe Healthcare industry average in the past year (10.1% vs 19.1%).
Earnings and Revenue History
Luz Saúde's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Luz Saúde Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTLS:LUZ Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 514.39 17.69 12.58
2018-03-31 498.41 17.35 12.06
2017-12-31 482.43 17.01 11.54
2017-09-30 471.05 16.54 10.96
2017-06-30 459.67 16.06 10.39
2017-03-31 454.11 15.59 9.73
2016-12-31 449.64 17.37 9.14
2016-09-30 449.30 19.43 8.24
2016-06-30 441.01 21.25 8.75
2016-03-31 431.31 22.62 8.22
2015-12-31 422.52 21.76 7.96
2015-09-30 416.33 19.91 8.96
2015-06-30 411.28 19.96 8.33
2015-03-31 404.87 18.78 8.51
2014-12-31 399.32 18.09 8.53
2014-09-30 390.03 19.20 6.84
2014-06-30 383.65 16.74 7.07
2014-03-31 379.09 16.31 6.99
2013-12-31 371.05 14.02 6.65
2013-09-30 368.92 13.04 7.84
2012-12-31 338.98 -2.12 7.55
2011-12-31 272.70 5.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Luz Saúde has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Luz Saúde used its assets less efficiently than the Europe Healthcare industry average last year based on Return on Assets.
  • Luz Saúde's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Luz Saúde's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Luz Saúde has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LUZ Health

 How is Luz Saúde's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Luz Saúde's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Luz Saúde is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Luz Saúde's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Luz Saúde's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Luz Saúde Company Filings, last reported 5 months ago.

ENXTLS:LUZ Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 244.64 308.20 43.10
2018-03-31 244.64 308.20 43.10
2017-12-31 235.38 299.54 57.78
2017-09-30 235.38 299.54 57.78
2017-06-30 227.15 288.00 33.51
2017-03-31 227.15 288.00 33.51
2016-12-31 217.05 254.11 41.49
2016-09-30 217.05 254.11 41.49
2016-06-30 210.86 242.49 22.61
2016-03-31 208.11 243.91 24.98
2015-12-31 203.71 217.00 29.41
2015-09-30 197.96 206.64 25.69
2015-06-30 192.32 210.90 24.00
2015-03-31 188.64 208.70 27.44
2014-12-31 183.21 221.07 20.68
2014-09-30 178.89 204.82 26.83
2014-06-30 173.17 205.80 22.16
2014-03-31 169.45 213.26 30.81
2013-12-31 143.21 244.39 34.82
2013-09-30 138.25 253.58 23.05
2012-12-31 128.94 275.76 24.26
2011-12-31 132.00 338.30 33.30
  • Luz Saúde's level of debt (126%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (193.1% vs 126% today).
  • Debt is well covered by operating cash flow (22%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.1x coverage).
X
Financial health checks
We assess Luz Saúde's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Luz Saúde has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LUZ Dividends

 What is Luz Saúde's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Luz Saúde dividends.
If you bought €2,000 of Luz Saúde shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Luz Saúde's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Luz Saúde's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTLS:LUZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 45 Stocks 1.5%
Portugal Market Average Dividend Yield Market Cap Weighted Average of 20 Stocks 4.9%
Portugal Minimum Threshold Dividend Yield 10th Percentile 1.5%
Portugal Bottom 25% Dividend Yield 25th Percentile 3.7%
Portugal Top 25% Dividend Yield 75th Percentile 7.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTLS:LUZ Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2016-03-15 0.000 0.000
2015-12-10 0.000 0.000
2015-11-12 0.000 0.000
2015-08-21 0.000 0.000
2015-08-10 0.000 0.000
2015-05-12 0.000 0.000
2015-05-08 0.000 0.000
2014-02-12 0.010 0.262

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Luz Saúde has not reported any payouts.
  • Unable to verify if Luz Saúde's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Luz Saúde's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Luz Saúde has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Luz Saúde's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Luz Saúde afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Luz Saúde has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LUZ Management

 What is the CEO of Luz Saúde's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Isabel Vaz
COMPENSATION €784,300
TENURE AS CEO 18.4 years
CEO Bio

Ms. Isabel Maria Pereira Aníbal Vaz has been Vice President of the Board at Luz Saúde, S.A. and has been its Chief Executive Officer since July 6, 2000. Ms. Vaz has been Director of Luz Saúde, S.A. since July 6, 2000 and serves as its Member of Advisory Board. Ms. Vaz has an undergraduate degree in chemical engineering from the Instituto Superior Técnico and an MBA from the Universidade Nova de Lisboa. She was a researcher at Instituto de Biologia Exper- imental e Tecnológica (1990 to 1991).

CEO Compensation
  • Isabel's compensation has been consistent with company performance over the past year.
  • Isabel's remuneration is higher than average for companies of similar size in Portugal.
Management Team Tenure

Average tenure of the Luz Saúde management team in years:

18.9
Average Tenure
  • The average tenure for the Luz Saúde management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jorge Manuel Batista Correia

TITLE
Chairman of the Board

Isabel Vaz

TITLE
VP of the Board
COMPENSATION
€784K
TENURE
18.4 yrs

João de Abreu Novais

TITLE
CFO & Director
COMPENSATION
€576K
TENURE
18.9 yrs

Ivo Antão

TITLE
Chief Information & Technology Officer and Director
COMPENSATION
€576K
TENURE
18.9 yrs

João Paulo da Cunha de Abreu Novais

TITLE
CFO & Director
TENURE
18.9 yrs

Nuno Pires

TITLE
Head of Finance & Accounting

João Rebelo

TITLE
Head of Legal & Compliance and Secretary

Marisa Morais

TITLE
Head of Marketing & Communication

Paulo Barreto

TITLE
Head of Human Resources

José Roquette

TITLE
President of Clinical Management Board
COMPENSATION
€9K
Board of Directors Tenure

Average tenure of the Luz Saúde board of directors in years:

13.8
Average Tenure
  • The average tenure for the Luz Saúde board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jorge Manuel Batista Correia

TITLE
Chairman of the Board
TENURE
3 yrs

Isabel Vaz

TITLE
VP of the Board
COMPENSATION
€784K
TENURE
18.4 yrs

Chen Qiyu

TITLE
Vice President of Board of Directors
TENURE
1.6 yrs

João de Abreu Novais

TITLE
CFO & Director
COMPENSATION
€576K
TENURE
13.8 yrs

Ivo Antão

TITLE
Chief Information & Technology Officer and Director
COMPENSATION
€576K
TENURE
13.8 yrs

João Paulo da Cunha de Abreu Novais

TITLE
CFO & Director
TENURE
13.8 yrs

Diogo Lucena

TITLE
Chairman of Advisory Board
COMPENSATION
€45K

Clara José de Sequeira Viegas Penha Ventura

TITLE
Chairman of Audit Board

João Carlos Jalles

TITLE
Chairman of Audit Board

António Castanheira Silva Lopes

TITLE
Chairman of Audit Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Luz Saúde's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Luz Saúde has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LUZ News

External News
Loading...
Simply Wall St News

Luz Saúde SA (ELI:LUZ): Assessing Capital Returns

and want a simplistic look at the return on Luz Saúde SA (ELI:LUZ) stock. … Your return is tied to LUZ’s ability to do this because the amount earned is used to invest in opportunities to grow the business or payout dividends, which are the two sources of return on investment. … Thus, to understand how your money can grow by investing in Luz Saúde, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE)

Simply Wall St -

Should You Be Concerned About Luz Saúde SA's (ELI:LUZ) ROE?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every €1 worth of equity in the company, it was able to earn €0.073. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Does Luz Saúde SA's (ELI:LUZ) CEO Salary Compare Well With Others?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … According to our data, Luz Saúde SA has a market capitalization of €530m, and pays its CEO total annual compensation worth €784k. … It would therefore appear that Luz Saúde SA pays Isabel Vaz more than the median CEO remuneration at companies of a similar size, in the same market

Simply Wall St -

Should You Be Concerned About Luz Saúde SA's (ELI:LUZ) Earnings Growth?

For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. … In this article, I will take a look at Luz Saúde SA's (ELI:LUZ) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … Despite a decline, did LUZ underperform the long-term trend and the industry.

Simply Wall St -

Should You Be Tempted To Sell Luz Saúde SA (ELI:LUZ) At Its Current PE Ratio?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to learn about the link between company’s fundamentals and stock market performance. … Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind.

Simply Wall St -

Luz Saúde SA (ELI:LUZ): What Are Investors Earning On Their Capital?

This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … Therefore, looking at how efficiently Luz Saúde is able to use capital to create earnings will help us understand your potential return. … Investors use many different metrics but the analysis below focuses on return on capital employed (ROCE).

Simply Wall St -

Is Luz Saúde SA (ELI:LUZ) A Financially Sound Company?

Investors are always looking for growth in small-cap stocks like Luz Saúde SA (ELI:LUZ), with a market cap of €539.81m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Does Luz Saúde SA.'s (ELI:LUZ) PE Ratio Signal A Selling Opportunity?

It compares a stock’s price per share to the stock’s earnings per share. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for LUZ Price per share = €5.4 Earnings per share = €0.181 ∴ Price-Earnings Ratio = €5.4 ÷ €0.181 = 29.8x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … LUZ’s P/E of 29.8x is higher than its industry peers (22.5x), which implies that each dollar of LUZ’s earnings is being overvalued by investors.

Simply Wall St -

With An ROE Of 7.35%, Has Luz Saúde SA.'s (ELI:LUZ) Management Done Well?

Check out our latest analysis for Luz Saúde Breaking down ROE — the mother of all ratios Return on Equity (ROE) is a measure of Luz Saúde’s profit relative to its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Luz Saúde’s equity capital deployed. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity ENXTLS:LUZ Last Perf May 1st 18 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient the business is with its cost management.

Simply Wall St -

Luz Saúde SA. (ELI:LUZ): Time For A Financial Health Check

With this growth in debt, the current cash and short-term investment levels stands at €57.80M , ready to deploy into the business. … Looking at LUZ’s most recent €142.60M liabilities, it appears that the company has been able to meet these commitments with a current assets level of €210.20M, leading to a 1.47x current account ratio. … In LUZ's case, the ratio of 4.04x suggests that interest is appropriately covered, which means that lenders may be inclined to lend more money to the company, as it is seen as safe in terms of payback.Next Steps: At its current level of cash flow coverage, LUZ has room for improvement to better cushion for events which may require debt repayment.

Simply Wall St -

LUZ Company Info

Map
Description

Luz Saúde, S.A. operates a network of healthcare facilities. Its hospitals and outpatient clinics offer medical and surgical specialties, including oncology, cardiovascular diseases, neurosciences, obesity, minimally invasive surgery, sports medicine and traumatology, long-term and palliative care, obstetrics, gynecology, gastrointestinal disorders, and others; and diagnostic tests, such as endoscopy, ultrasound, general radiology, computed tomography, magnetic resonance imaging, and angiography, as well as urgent care services. The company also residential hospitals specialized in healthcare services that involve rehabilitation, medical or post-operative convalescence, neuro-stimulation, general support for dementia, continued care, palliative and geriatric care; a radiotherapy unit; and senior residence units for individuals of 65 years and older. It provides its services through 20 units, including 10 private hospitals, 1 national health service hospital operated under a Public-Private Partnership, 7 private outpatient clinics, and 2 senior residences located in the Northern, Central, and Southern-Central regions of Portugal. The company was formerly known as Espírito Santo Saúde-SGPS, S.A. and changed its name to Luz Saúde, S.A. in February 2015. The company was founded in 2000 and is headquartered in Lisbon, Portugal. Luz Saúde, S.A. is a subsidiary of Fidelidade – Companhia de Seguros, S.A.

Details
Name: Luz Saúde, S.A.
LUZ
Exchange: ENXTLS
Founded: 2000
€535,036,622
95,542,254
Website: http://www.luzsaude.pt
Address: Luz Saúde, S.A.
Rua Carlos Alberto da Mota Pinto, 17,
9th Floor,
Lisbon,
Lisbon, 1070-313,
Portugal
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTLS LUZ Common Stock Euronext Lisbon PT EUR 12. Feb 2014
LSE 0QRX Common Stock London Stock Exchange GB EUR 12. Feb 2014
Number of employees
Current staff
Staff numbers
6,453
Luz Saúde employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/03 19:23
End of day share price update: 2018/11/22 00:00
Last earnings filing: 2018/09/20
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.